Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GIP and Semaglutide in Type 2 Diabetes
NCT05078255Completed
- Start
- Jan 2022
- Primary completion
- Jan 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial of glucose-dependent insulinotropic polypeptide[1-42] in type 2 diabetes mellitus (T2DM). Started Jan 2022; status: completed.
02
Drugs
glucose-dependent insulinotropic polypeptide[1-42]
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05078255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05078255.